KAS1_KASSE
ID KAS1_KASSE Reviewed; 21 AA.
AC P0C010;
DT 07-JUN-2005, integrated into UniProtKB/Swiss-Prot.
DT 07-JUN-2005, sequence version 1.
DT 25-MAY-2022, entry version 33.
DE RecName: Full=Kassinatuerin-1;
OS Kassina senegalensis (Senegal running frog).
OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Amphibia;
OC Batrachia; Anura; Neobatrachia; Microhyloidea; Hyperoliidae; Kassina.
OX NCBI_TaxID=8415;
RN [1]
RP PROTEIN SEQUENCE, SYNTHESIS, FUNCTION, MASS SPECTROMETRY, AND AMIDATION AT
RP ILE-21.
RC TISSUE=Skin;
RX PubMed=10679222; DOI=10.1006/bbrc.2000.2136;
RA Mattute B., Knoop F.C., Conlon J.M.;
RT "Kassinatuerin-1: a peptide with broad-spectrum antimicrobial activity
RT isolated from the skin of the hyperoliid frog, Kassina senegalensis.";
RL Biochem. Biophys. Res. Commun. 268:433-436(2000).
RN [2]
RP SYNTHESIS, FUNCTION, MINIMAL INHIBITORY CONCENTRATION, AND MUTAGENESIS OF
RP GLY-7; ALA-13; SER-18 AND ASP-19.
RX PubMed=15885852; DOI=10.1016/j.peptides.2005.04.003;
RA Conlon J.M., Abraham B., Galadari S., Knoop F.C., Sonnevend A., Pal T.;
RT "Antimicrobial and cytolytic properties of the frog skin peptide,
RT kassinatuerin-1 and its L- and D-lysine-substituted derivatives.";
RL Peptides 26:2104-2110(2005).
CC -!- FUNCTION: Shows broad-spectrum antimicrobial activity against the Gram-
CC negative bacterium E.coli (MIC=6.25 uM), K.pneumoniae (MIC=25 uM),
CC E.cloacae (MIC=6.25 uM), P.aeruginosa (MIC=25 uM), the Gram-positive
CC bacterium S.aureus (MIC=6.25 uM), S.epidermidis (MIC=6.25 uM),
CC E.faecalis (MIC=12.5 uM), and the fungus C.albicans (MIC=100 uM). Has
CC no antimicrobial effect against P.mirabilis (MIC>100 uM). Has
CC relatively high cytolytic and hemolytic activities. Its alpha-helix has
CC considerable amphipathic character. {ECO:0000269|PubMed:10679222,
CC ECO:0000269|PubMed:15885852}.
CC -!- SUBCELLULAR LOCATION: Secreted.
CC -!- TISSUE SPECIFICITY: Expressed by the skin dorsal glands.
CC -!- MASS SPECTROMETRY: Mass=2282.5; Method=Electrospray;
CC Evidence={ECO:0000269|PubMed:10679222};
CC -!- MISCELLANEOUS: This peptide was also synthesized without its N-terminal
CC amidation. This modification decreases its antimicrobial and hemolytic
CC activities.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR AlphaFoldDB; P0C010; -.
DR GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR GO; GO:0050832; P:defense response to fungus; IEA:UniProtKB-KW.
DR GO; GO:0044179; P:hemolysis in another organism; IEA:UniProtKB-KW.
PE 1: Evidence at protein level;
KW Amidation; Antibiotic; Antimicrobial; Cytolysis; Direct protein sequencing;
KW Fungicide; Hemolysis; Secreted.
FT PEPTIDE 1..21
FT /note="Kassinatuerin-1"
FT /id="PRO_0000043808"
FT MOD_RES 21
FT /note="Isoleucine amide"
FT /evidence="ECO:0000269|PubMed:10679222"
FT MUTAGEN 7
FT /note="G->K: When associated with K-19, no change in
FT antibacterial activity against E.coli and S.aureus, 2-fold
FT increase in antimicrobial activity against C.albicans,
FT little increase in hemolytic activity. When associated with
FT K-18 and K-19, no change in antibacterial activity against
FT E.coli and S.aureus, 4-fold increase in antimicrobial
FT activity against C.albicans, little increase in hemolytic
FT activity."
FT /evidence="ECO:0000269|PubMed:15885852"
FT MUTAGEN 13
FT /note="A->K: Loss of antimicrobial activity, loss of
FT hemolytic activity."
FT /evidence="ECO:0000269|PubMed:15885852"
FT MUTAGEN 18
FT /note="S->K: When associated with K-19, no change in
FT antibacterial activity against E.coli, 2-fold increase in
FT antibacterial activity against S.aureus, 4-fold increase in
FT antimicrobial activity against C.albicans, 2.6-fold
FT increase in hemolytic activity. When associated with K-7
FT and K-19, no change in antibacterial activity against
FT E.coli and S.aureus, 4-fold increase in antimicrobial
FT activity against C.albicans, little increase in hemolytic
FT activity."
FT /evidence="ECO:0000269|PubMed:15885852"
FT MUTAGEN 19
FT /note="D->K: No change in antibacterial activity against
FT E.coli, 2-fold increase in antibacterial activity against
FT S.aureus, 2-fold increase in antimicrobial activity against
FT C.albicans, little increase in hemolytic activity. When
FT associated with K-18, no change in antibacterial activity
FT against E.coli, 2-fold increase in antibacterial activity
FT against S.aureus, 4-fold increase in antimicrobial activity
FT against C.albicans, 2.6-fold increase in hemolytic
FT activity. When associated with K-7, no change in
FT antibacterial activity against E.coli and S.aureus, 2-fold
FT increase in antimicrobial activity against C.albicans,
FT little increase in hemolytic activity. When associated with
FT K-18 and K-7, no change in antibacterial activity against
FT E.coli and S.aureus, 4-fold increase in antimicrobial
FT activity against C.albicans, little increase in hemolytic
FT activity."
FT /evidence="ECO:0000269|PubMed:15885852"
SQ SEQUENCE 21 AA; 2284 MW; 86E8E32C8798C4E3 CRC64;
GFMKYIGPLI PHAVKAISDL I
